Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM2 | Q14416 | 2/20 | 0.41 |
| ▸ | TGFBR1 | P36897 | 12/20 | 0.39 |
| ▸ | FASN | P49327 | 1/20 | 0.34 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.34 |
| ▸ | MAT2A | P31153 | 1/20 | 0.33 |
| ▸ | RXRA | P19793 | 1/20 | 0.32 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.32 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20575907 | 0.92 | TGFBR1 (0.37) | GRM2TGFBR1FASNMAT2A | |
| SCHEMBL20575480 | 0.85 | FASN (0.35) | TGFBR1FASNRXRAGRIN1GRIN2B | |
| SCHEMBL20575609 | 0.83 | FASN (0.35) | TGFBR1FASN | |
| SCHEMBL20575640 | 0.83 | SLC6A2 (0.37) | RXRAGRIN1GRIN2B | |
| SCHEMBL20575894 | 0.83 | FASN (0.39) | GRM2TGFBR1FASN | |
| SCHEMBL20575463 | 0.83 | FASN (0.35) | TGFBR1FASNMAT2A | |
| SCHEMBL20575462 | 0.82 | TGFBR1 (0.37) | TGFBR1FASNRXRAGRIN1GRIN2B | |
| SCHEMBL20575432 | 0.80 | TGFBR1 (0.43) | TGFBR1 | |
| SCHEMBL20575368 | 0.79 | MAPT (0.35) | FASN | |
| SCHEMBL20575626 | 0.79 | FASN (0.38) | GRM2TGFBR1FASN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180346487-A1 | Fused Imidazole Derivatives as TGF-Beta Inhibitors | MIDCAP FINANCIAL TRUST | 2018-12-06 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180346487-A1 | Fused Imidazole Derivatives as TGF-Beta Inhibitors | TGFBR1, TGFBR2, SMAD3 | GRM2 2719/4885TGFBR1 1/4885FASN 3875/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.